for psoriasis be interrupted in the era of COVID-19?" 1 . We share the concern that has been expressed about the possible impact of biologic therapies on the patient's susceptibility to COVID-19 infection. In addition to the infectious complications for biologic therapies reported during pivotal trials for psoriasis, we would like to draw attention to other aspects that might guide the decision whether to continue biologic therapy during the COVID-19 pandemic. with COVID-19, has been hypothesized to be caused more by an exaggerated immune response than the virus itself 3 . This implies that immune dysregulation is regarded as a highly important therapeutic target; a clinical trial is currently evaluating adalimumab in severe COVID-19 pneumonia 4 . Notably, a significant elevation in TNF-alpha and also IL-17 was found in plasma samples of patients with Middle East respiratory syndrome coronavirus (MERS)-CoV 5 , another respiratory disease caused by similar coronaviruses and associated with high morbidity and mortality. In contradistinction, IL-12 blockade might impair the antiviral cytokine IFN-γ 3 production. However, it must also be noted that patients with inherited defects in IL-12 signaling do not seem to be as severely impacted by infection with respiratory viruses.
Italy is strongly involved with COVID-19. Presently, an operating instruction on biologic therapies has been implemented in our hospital immunology 
